- Home
- PETS vs CLSD Comparison
PETS vs CLSD Comparison
Compare PETS & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- CLSD
- Stock Information
- Founded
- PETS 1996
- CLSD 2011
- Country
- PETS United States
- CLSD United States
- Employees
- PETS N/A
- CLSD N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- CLSD Health Care
- Exchange
- PETS Nasdaq
- CLSD Nasdaq
- Market Cap
- PETS 62.8M
- CLSD 59.1M
- IPO Year
- PETS N/A
- CLSD 2016
- Fundamental
- Price
- PETS $3.24
- CLSD $0.84
- Analyst Decision
- PETS Sell
- CLSD Strong Buy
- Analyst Count
- PETS 2
- CLSD 5
- Target Price
- PETS $3.35
- CLSD $4.80
- AVG Volume (30 Days)
- PETS 127.2K
- CLSD 435.5K
- Earning Date
- PETS 08-05-2025
- CLSD 08-11-2025
- Dividend Yield
- PETS N/A
- CLSD N/A
- EPS Growth
- PETS N/A
- CLSD N/A
- EPS
- PETS 0.02
- CLSD N/A
- Revenue
- PETS $247,010,000.00
- CLSD $3,764,000.00
- Revenue This Year
- PETS N/A
- CLSD $60.52
- Revenue Next Year
- PETS N/A
- CLSD $88.28
- P/E Ratio
- PETS $189.87
- CLSD N/A
- Revenue Growth
- PETS N/A
- CLSD N/A
- 52 Week Low
- PETS $2.90
- CLSD $0.70
- 52 Week High
- PETS $6.85
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- PETS 33.34
- CLSD 56.38
- Support Level
- PETS $3.36
- CLSD $0.78
- Resistance Level
- PETS $3.67
- CLSD $0.82
- Average True Range (ATR)
- PETS 0.20
- CLSD 0.04
- MACD
- PETS -0.08
- CLSD 0.01
- Stochastic Oscillator
- PETS 0.00
- CLSD 91.50
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.